Gilead’s HCV Drug Sofosbuvir Picks Up Easy FDA Panel Endorsement
This article was originally published in The Pink Sheet Daily
Executive Summary
Antiviral Drugs Advisory Committee unanimously recommends approval in HCV genotypes 1-4 and supports use in a subgroup of patients awaiting liver transplant, but says more data are needed in transplant patients with more severe disease.